Swing Trading Opportunity: Amgen (AMGN) Dividend Play ($2.13 per share) on June 08, 2023.
Swing trading involves capturing short-term price movements in stocks, and taking advantage of market fluctuations. In this article, we will analyze Amgen (AMGN), a high-capitalization stock, and explore a potential swing trading opportunity surrounding its upcoming dividend payment. By understanding the dividend schedule and its implications for traders, we can assess the potential for capitalizing on this event.
Amgen (AMGN) has announced a dividend payment of $2.13 per share, scheduled to be paid on June 08, 2023. The record date for this dividend is also June 08, 2023, while the ex-dividend date is set for May 17, 2023. It is important to note that the ex-dividend date is typically set a few business days before the record date.
For swing traders interested in Amgen (AMGN), the ex-dividend date is a crucial factor to consider. The ex-dividend date serves as a cut-off point determining who is entitled to receive the upcoming dividend payment. If shares are purchased on or after the ex-dividend date (May 17, 2023, in this case), the buyer will not be eligible to receive the dividend payment. Instead, the dividends are retained by the seller. However, if the stocks are purchased before the ex-dividend date, the buyer will be entitled to receive the dividend.
AMGN's RSI Indicator leaves overbought zone
The 10-day RSI Oscillator for AMGN moved out of overbought territory on February 26, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 instances where the indicator moved out of the overbought zone. In of the 45 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on March 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMGN as a result. In of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for AMGN turned negative on March 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AMGN broke above its upper Bollinger Band on February 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in of 313 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 236 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.989) is normal, around the industry mean (9.311). P/E Ratio (25.968) is within average values for comparable stocks, (22.655). Projected Growth (PEG Ratio) (2.475) is also within normal values, averaging (2.275). Dividend Yield (0.026) settles around the average of (0.025) among similar stocks. P/S Ratio (5.450) is also within normal values, averaging (3.943).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor
Advertisement